<DOC>
	<DOCNO>NCT01370135</DOCNO>
	<brief_summary>Proliferative ischemic retinopathy lead formation abnormal vessel iris surface induce increase level vascular endothelial growth factor ( VEGF ) . In progressive stage fibrovascular membrane occlude anterior chamber angle inhibit aqueous outflow result neovascular glaucoma . The increased intraocular pressure often difficult control frequently result loss vision . The aim study analyze short- long-term outcome adjuvant intraocular Ranibizumab application patient neovascular glaucoma rubeosis analyze role ranibizumab within holistic treatment regime .</brief_summary>
	<brief_title>Study Evaluate Effects Ranibizumab ( Lucentis ) Patients With Rubeosis Neovascular Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Neovascular</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1. neovascular glaucoma rubeosis definition neovascular glaucoma : patient iris neovascularization intraocular pressure elevation ( exceed 21 mmHg ) definition rubeosis : patient iris neovascularization without intraocular pressure elevation ( ≤21 mmHg ) 2. available followup 12 month 3. write informed consent 4. visual acuity light perception well . 1. history evidence severe cardiac disease ( e.g. , NYHA functional class III IV ) 2. clinical medical history unstable angina , acute coronary syndrome , myocardial infarction revascularization 6 month 3. ventricular tachyarrhythmias require ongoing treatment 4 . History evidence clinically significant peripheral vascular disease , intermittent claudication prior amputation 5 . Clinically significant impair renal hepatic function 6 . Stroke within 12 month trial entry . 7 . Known serious allergy fluorescein dye use angiography 8 . Known contraindication component Lucentis® formulation . Ocular concomitant conditions/ diseases 1 . Active intraocular inflammation ( grade trace ) either eye 2 . Any active infection ( e.g . conjunctivitis , keratitis , scleritis , uveitis , endophthalmitis ) either eye 3 . History uveitis either eye 4 . Treatment antiangiogenic drug ( pegaptanib sodium , anecortave acetate , bevacizumab , ranibizumab , etc . ) intravitreal corticosteroid either eye within 4 month prior inclusion 5 . Angle block glaucoma 6 . Phthisis 7 . Intraocular Pressure &lt; 10mmHg Compliance/ Administrative 1 . Previous participation clinical study investigational drug ( exclude vitamin mineral ) within 1 month ( period correspond 5 halflives investigational drug , whatever long ) prior inclusion 2 . Women childbearing potential , defined woman physiologically capable become pregnant . include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS use two birth control method . The two method double barrier method barrier method plus hormonal method . Adequate barrier method contraception include : diaphragm , condom ( partner ) , intrauterine device ( copper hormonal ) , sponge spermicide . Hormonal contraceptive include market contraceptive agent include estrogen and/or progestational agent . 3 . Pregnant nursing ( lactate ) woman 4 . Inability comply study followup procedure . 5 . Any treatment investigational agent past 60 day condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>neovascular glaucoma</keyword>
	<keyword>rubeosis</keyword>
	<keyword>anterior chamber</keyword>
	<keyword>intraocular</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>short an longterm effect</keyword>
	<keyword>best correct visual acuity</keyword>
	<keyword>gonioscopy</keyword>
	<keyword>BCVA</keyword>
	<keyword>quality life</keyword>
</DOC>